Sidley Austin represented Pyxis Oncology, Inc. on the deal. Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company, announced that it agreed to sell 8,849,371 shares of...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Pyxis Oncology on the deal. Pyxis Oncology (“Pyxis” or the “Company”) announced the closing of a $152 million...
You must be a Standard 1 Year member to access this content.
